UPDATE: Roka Eyes Net Proceeds of $78M from Planned IPO | GenomeWeb

The story has been corrected to state that Roka's technology is based on transcription mediated amplification methods, not PCR technology.

NEW YORK (GenomeWeb) – Roka Bioscience said on Monday that it anticipates raising as much as $77.8 million from its planned initial public offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.